KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways

KineMed Inc. (www.kinemed.com) today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches towards metabolic disease, in particular Type II Diabetes. The collaboration will employ KineMed's unique dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.

“We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform”

Diabetes is an emerging global healthcare epidemic with an estimated 347 million people affected, according to the WHO. Diabetes is predicted to become the seventh leading cause of death in the world by the year 2030 and total deaths from diabetes are projected to rise by more than 50% in the next 10 years.

In the United States Type II diabetes affects over one quarter of Americans over the age of 65. Diabetes is a major cause of heart disease and stroke, and is now also the leading cause of kidney failure, non-traumatic lower-limb amputations and new cases of blindness among adults.

Despite 50 years of drug research, over 60% of patients remain unresponsive to current therapies, requiring novel approaches to address fundamental metabolic processes in diabetes.

"We are very pleased to announce the renewal of this ongoing partnership in an important area of medicine that affects so many Americans. Powerful discovery and investigative abilities of novel disease pathways are key strengths of our translational platform," said Dr. Scott Turner, Executive Vice-President, R&D at KineMed. "We look forward to continuing to work with Pfizer to accelerate and rapidly de-risk the advancement of novel compounds in pre-clinical and clinical trials."

Source:

KineMed, Inc.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Pfizer, Inc.. (2013, June 12). KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways. News-Medical. Retrieved on May 20, 2019 from https://www.news-medical.net/news/20130328/KineMed-renews-research-collaboration-with-Pfizer-for-advancement-of-novel-diabetes-pathways.aspx.

  • MLA

    Pfizer, Inc.. "KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways". News-Medical. 20 May 2019. <https://www.news-medical.net/news/20130328/KineMed-renews-research-collaboration-with-Pfizer-for-advancement-of-novel-diabetes-pathways.aspx>.

  • Chicago

    Pfizer, Inc.. "KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways". News-Medical. https://www.news-medical.net/news/20130328/KineMed-renews-research-collaboration-with-Pfizer-for-advancement-of-novel-diabetes-pathways.aspx. (accessed May 20, 2019).

  • Harvard

    Pfizer, Inc.. 2013. KineMed renews research collaboration with Pfizer for advancement of novel diabetes pathways. News-Medical, viewed 20 May 2019, https://www.news-medical.net/news/20130328/KineMed-renews-research-collaboration-with-Pfizer-for-advancement-of-novel-diabetes-pathways.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
CHOP, Pfizer join forces to expedite novel treatments for children